Información: Esta es una versión obsoleta del modelo de datos. En la sección izquierda, bajo "Versiones", se encuentra el historial de versiones. Puede acceder a la versión actual a través del siguiente link: here.
Información:
Error:
ID
34550
Descripción
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT01156311
Link
https://clinicaltrials.gov/show/NCT01156311
Palabras clave
Versiones (2)
- 19/1/19 19/1/19 -
- 21/5/19 21/5/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
19 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Relapsing-Remitting Multiple Sclerosis NCT01156311
Eligibility Relapsing-Remitting Multiple Sclerosis NCT01156311
- StudyEvent: Eligibility
Similar models
Eligibility Relapsing-Remitting Multiple Sclerosis NCT01156311
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
must have a confirmed diagnosis of relapsing-remitting multiple sclerosis (rrms) according to mcdonald criteria #1-4 (polman et al, 2005 [appendix i]), and have a prior brain magnetic resonance imaging (mri) demonstrating lesion (s) consistent with multiple sclerosis (ms) from any point in time.
boolean
ID.2
Item
must have an expanded disability status scale (edss) between 0.0 and 5.0, inclusive.
boolean
ID.3
Item
must be taking the same dose of a prescribed ifnβ (either avonex, betaseron, rebif) or ga for at least 12 months consecutively at the time of enrollment and remain on this treatment for the duration of the study. participants receiving rebif must be prescribed 44 μg by subcutaneous injection three times per week.
boolean
ID.4
Item
key exclusion criteria:
boolean
ID.5
Item
primary progressive, secondary progressive, or progressive relapsing ms (as defined by polman et al. 2005).
boolean
ID.6
Item
other chronic disease of the immune system, malignancies, acute urologic, or pulmonary disease.
boolean
ID.7
Item
pregnant or nursing women.
boolean
ID.8
Item
participation within 6 months prior to study enrollment in any other drug, biologic, or device study.
boolean
ID.9
Item
note: other protocol-defined inclusion/exclusion criteria may apply.
boolean